8-K: Goldenwell Biotech Changes Auditor Amid Going Concern Doubt

Goldenwell Biotech, Inc. announced a change in its independent registered public accounting firm, with KCCW Accountancy Corp. resigning and Michael Gillespie & Associates, PLLC appointed, following KCCW's going concern warning.

Summary

• KCCW Accountancy Corp. resigned as Goldenwell Biotech, Inc.'s independent registered public accounting firm on July 24, 2025.
• Michael Gillespie & Associates, PLLC was engaged as the Company's new independent registered public accountants on August 14, 2025.
• KCCW's audit reports for the fiscal years ended December 31, 2024, and 2023, contained no adverse opinion or disclaimer, nor were they qualified or modified as to uncertainty, audit scope, or accounting principle.
• KCCW's report, however, stated that there is substantial doubt about the Company's ability to continue as a going concern.
• The Company reported no disagreements with KCCW on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.
• Michael Gillespie & Associates previously served as the Company's independent registered public accounting firm from November 14, 2024, until January 23, 2025, and reviewed financial statements for the fiscal quarter ended September 30, 2024.

Sentiment

Score: 3

Explanation: The primary negative factor is the former auditor's explicit statement of 'substantial doubt about the Company's ability to continue as a going concern,' which indicates significant financial instability. While there were no reported disagreements with the former auditor, the going concern warning overshadows this.

Positives

• No disagreements on accounting principles or auditing procedures were reported between the Company and its former auditor, KCCW Accountancy Corp.
• The newly appointed auditor, Michael Gillespie & Associates, PLLC, has prior experience with the Company, having served from November 2024 to January 2025.

Negatives

• The former independent registered public accounting firm, KCCW Accountancy Corp., stated 'substantial doubt about the Company's ability to continue as a going concern' in their reports for the fiscal years ended December 31, 2024, and 2023.

Risks

• Substantial doubt about the Company's ability to continue as a going concern, as explicitly stated by the former independent auditor, KCCW Accountancy Corp.

Future Outlook

NA

Management Comments

• The Company provided KCCW a copy of the disclosures and requested KCCW to furnish a letter to the Securities and Exchange Commission stating whether or not it agrees with the statements.
• The Company did not have any disagreements with KCCW and therefore did not discuss any past disagreements with Michael Gillespie & Associates.

Industry Context

The change in auditor, particularly when accompanied by a 'going concern' warning, is a significant event in the biotech industry, often signaling financial distress or challenges in securing adequate funding for research, development, or commercialization. While auditor changes are common, a going concern warning from a resigning auditor is a serious red flag that warrants close scrutiny by investors and stakeholders, as it indicates potential liquidity issues or an inability to meet financial obligations in the near term.

Comparison to Industry Standards

• The 'going concern' warning issued by KCCW Accountancy Corp. for Goldenwell Biotech, Inc. is a critical deviation from the financial health typically expected of stable, publicly traded companies in the biotech sector. Healthy biotech firms, especially those with promising pipelines or commercialized products, generally do not receive such warnings, which are indicative of significant financial instability.
• While specific comparable companies or projects are not mentioned in the filing, a going concern warning places Goldenwell Biotech, Inc. in a category of higher financial risk compared to peers that maintain strong balance sheets and consistent funding, such as established pharmaceutical companies or well-funded clinical-stage biotechs.

Stakeholder Impact

• Shareholders: Face increased risk due to the 'going concern' warning, which implies potential for significant dilution, financial restructuring, or even insolvency, potentially leading to a loss of investment.
• Creditors: May view the Company as a higher credit risk, potentially impacting terms for future financing or increasing scrutiny on existing debt obligations.
• Employees: Could experience uncertainty regarding job security and the Company's long-term viability.

Key Dates

Recommendation

The former auditor's explicit statement of 'substantial doubt about the Company's ability to continue as a going concern' is a severe red flag, indicating significant financial distress and potential insolvency. While the company reported no disagreements with the former auditor, the going concern warning suggests fundamental financial instability that warrants a sell recommendation for risk-averse investors.

Keywords

Biotech, Auditor Change, SEC Filing, Going Concern, Financial Reporting, Public Accounting, Corporate Governance